Scientists discover bacterial cause behind fatal heart complications

May 15, 2015
Scientists discover bacterial cause behind fatal heart complications

Researchers at the University of Liverpool's Institute of Infection and Global Health have discovered a key cause of life threatening heart complications, conditions that frequently follow severe infections with the bacteria responsible for pneumonia and meningitis.

Streptococcus pneumoniae is a major human pathogen and is known to be associated with increased risk of fatal complications including heart failure and heart attacks.

As Streptococcus pneumoniae is a respiratory pathogen that does not infect the heart, however, the association with heart problems has puzzled clinicians and researchers, particularly as prompt use of antibiotics does not provide any protection from cardiac complications.

Heart injury

A multidisciplinary research team, led by Professor Aras Kadioglu and Professor Cheng-Hock Toh at the University, has now shown that the cause of cardiac injury is a toxin called pneumolysin, which is released by the bacteria during infection. They found that this toxin could directly attack heart , causing injury, damage and death.

Dr Yasir Alhamdi, from the University's Institute of Infection and Global Health and lead author of the study, said: "We have discovered that the toxin pneumolysin, which is released during infection with Streptococcus pneumoniae, is the main reason why a significant number of patients develop rapidly progressive and fatal heart complications even if the bacteria does not directly infect the heart."

Importantly, the researchers also found that the use of antibiotics could exacerbate damage to cells during infection with Streptococcus pneumoniae, as antibiotic-induced bacterial death releases large amounts of pneumolysin into the blood circulation.

Engineered fats

To circumvent this problem, the team used specially engineered fat bodies, called liposomes, to bind to and neutralise pneumolysin and prevent it from damaging . Liverpool researchers had previously shown that liposome therapy could be used as a treatment against pneumonia and sepsis caused by Streptococcus pneumoniae and MRSA.

Dr Daniel Neill, who conducted the infection model work, said: "We have now shown that liposomes can also be used therapeutically to combat deadly that accompany infections caused by Streptococcus pneumoniae.

"This exciting new finding demonstrates that liposomes may also be of use in conjunction with antibiotics to mitigate the pathological effects of antibiotic-induced bacterial lysis."

Explore further: How pneumonia bacteria can compromise heart health

More information: "Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection." PLoS Pathog 11(5): e1004836. DOI: 10.1371/journal.ppat.1004836

Related Stories

How pneumonia bacteria can compromise heart health

September 19, 2014

Bacterial pneumonia in adults carries an elevated risk for adverse cardiac events (such as heart failure, arrhythmias, and heart attacks) that contribute substantially to mortality—but how the heart is compromised has been ...

Study ties dental drugs, heart infection risk

November 18, 2014

A study suggests that curbing the routine use of preventive antibiotics before dental work may have contributed to a rise in heart valve infections in England.

Recommended for you

$460-mn vaccine push to 'outsmart' viruses

January 19, 2017

With the world still reeling from outbreaks of deadly Ebola and baby-deforming Zika, governments and charities launched a $460-million (431 million-euro) initiative Thursday to "outsmart" infectious epidemics.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.